Latest Breaking News On - Advances phase - Page 1 : comparemela.com

Aptevo Therapeutics Reports First Quarter 2021 Financial Results Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therapeutics Inc. ( Aptevo or the Company ) (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today reported its financial results for the quarter ended March 31, 2021. We are pleased to report progress in the clinical trial of our ADAPTIR platform candidate APVO436, with the dose limiting toxicity (DLT) evaluation in cohorts 1 through 9 now completed and 44 patients enrolled to date in cohorts 1-10. We remain confident in the clinical impact potential of APVO436 and our platform technologies, and look forward to sharing interim data readouts from our ongoing APVO436 study later this year,

Marvin whiteExchange commissionDevelopment expensesAptevo therapeutics incHealthcare royalty managementPfizer incAptevo biotherapeuticsAdvances phaseAcute myeloid leukemiaHigh grade myelodysplastic syndromeAptevo therapeuticsResults summaryRoyalty purchase agreementInvestment amountMilestone amountsMidcap financial